The first therapeutic attempts with targeted therapy derive from mAbs directed toward HER2 (trastuzumab and then pertuzumab), which, when administered alone or in combination with chemotherapy, have not demonstrated activity either in pretreated or naïve patients, nor in patients with HER2 OE or AMP NSCLC; however, above all, they have also been disappointing even in patients with HER2 MUT NSCLC [53,54,55,56,57,58,59,60,61]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.